ESCITALOPRAM OXALATE | N219130 | ALMATICA PHARMA LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Lachman Consulting Services, Inc. FDA-2026-P-4103 · 6 docket documents Lachman Consulting Services, Inc. filed this suitability petition on behalf of a client requesting that the FDA declare Escitalopram Oxalate Tablets, 15 mg suitable for submission as an ANDA under Section 505(j)(2)(C) of the FD&C Act. The proposed product, a new strength intermediate between the ref | Suitability | 2026-04-15 | Open | Lachman Consulting Services, Inc. |
Lachman Consultant Services, Inc. - Citizen Petition FDA-2007-P-0297 · 6 docket documents Lachman Consultant Services, Inc. filed this petition on behalf of a client requesting the FDA declare that Escitalopram Oxalate Orally Dissolving Film Strips in 5 mg, 10 mg, and 20 mg strengths is suitable for consideration in an abbreviated new drug application under Section 505(j)(2)(C), using Le | Other | 2008-05-22 | Withdrawn | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$5.42
per ea
Lowest NADAC/Unit
$5.42
per ea
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 52427079530ESCITALOPRAM 15 MG CAPSULE | $5.42 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.